The basics:
- Sickle cell anemia now qualifies for New Jersey Medicinal Cannabis Program
- Cannabis access aims to alleviate chronic pain, inflammation, improve sleep
- NJ Cannabis Regulatory Commission administers program with regulated patient access
- Expansion addresses health disparities, supporting Black and brown communities
New Jersey has added sickle cell anemia as a qualifying condition for the state’s Medicinal Cannabis Program.
Under a measure signed Jan. 12 by outgoing Gov. Phil Murphy, patients diagnosed with the blood disorder are now able to access medical marijuana through New Jersey’s regulated program.
State Sens. Shirley Turner, D-15th District, and Angela McKnight, D-31st District, served as primary sponsors of Senate Bill 2392. Companion legislation backers included Assemblywoman Verlina Reynolds-Jackson, D-15th District, and Assemblyman William Spearman, D-5th District.
An inherited blood disorder, sickle cell anemia can cause severe, recurring pain and other complications. Often, episodes require hospitalization and can impact daily functioning, according to Mayo Clinic.
Studies have shown that medical cannabis may help alleviate chronic and nerve-related pain, reduce inflammation, improve sleep and lower reliance on opioids, Healthline reported.
Of the estimated 100,000 Americans affected by the disease, more than 90% identify as non-Hispanic Black or African American, U.S. Centers for Disease Control and Prevention data shows.
Turner noted, “Sickle cell disease disproportionately affects Black and Brown communities, where patients often experience barriers to care and stigma around pain management.”
“By allowing patients with sickle cell anemia to access medical cannabis through New Jersey’s regulated program, we are providing compassionate, equitable treatment that centers on dignity and quality of life,” she stated.
McKnight added, “Expanding access to medical cannabis gives individuals more options to manage their symptoms, improve their overall well-being, and achieve a better quality of life.”
‘A meaningful expansion’
The state medicinal program allows registered patients under the care of licensed health care practitioners to safely access cannabis-based medicine from regulated and monitored facilities. The New Jersey Cannabis Regulatory Commission administers the initiative.
Recreational cannabis has been legally sold in New Jersey since April 2022. However, medical patients continue to receive several benefits under the program. Perks include priority access to products and the ability to purchase up to 84 grams every 30 days without state sales tax.
After enacting its medical marijuana law in 2010, New Jersey has expanded the program to cover a wide range of conditions, such as:
- Cancer
- Chronic pain
- Glaucoma
- Multiple sclerosis
- Post-traumatic stress disorder
- Seizure disorders
Following Murphy’s signing of the bill, the CRC described it as “a meaningful expansion of regulated patient access to therapeutic options aimed at managing chronic pain and other symptoms associated with sickle cell disease.”
The addition comes as enrollment in the MCP continues to trend downward following the launch of adult-use market. As of January 2026, there are 50,798 participants, down from 128,548 in April 2022.